During the 2023 AASLD The Liver Meeting, we hosted an insightful industry event exploring The Future of Pathology in MASH Clinical Trials. We had the privilege to connect with many leaders involved in MASH clinical trials and share recent advancements with our AI-powered digital pathology solutions.

Kicking off the presentations, Prof. Stephen A. Harrison provided an overview focused on the impact of steatosis and liver volume reductions on fibrosis in MASH trials. As certain drugs can potently reduce fat content and liver volumes over short time periods, Prof. Harrison explained how these reductions can potentially impact interpretations of fibrosis if not adequately accounted for. He went on to demonstrate how HistoIndex’s qFibrosis technology incorporates procedures to normalize for these reductions, enabling improved detection of fibrosis changes.

Up next, Dr. Dean Tai shared valuable perspectives stemming from the recent FDA Non-invasive Tests (NITs) biomarker workshop, including remaining gaps that need to be addressed before biomarkers can be assessed as surrogate endpoints in MASH trials.